Back to News
Market Impact: 0.1
Medicenna Reports Potent CD122 Blockade and Extended Survival with MDNA209 in Preclinical Models of Autoimmune Disease
Source: globenewswire.com
Healthcare & BiotechTechnology & Innovation
MDNA209 is a potential first-in-class engineered Superkine designed to block CD122 and inhibit IL-2 and IL-15 signaling. The approach is intended to suppress overactive immune cells involved in inflammatory and autoimmune conditions; no clinical results or financial figures are provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
More News
- A shock in Brazil sends stocks plunging, while neoclouds take another hit
- Anthropic’s IPO filing shows explosive growth, risks and staggering costs
- Elon Musk warns more than 200 AI cloud companies face ‘guppy-level death’ as the AI boom runs into a debt crisis
- Anthropic Files for IPO While Warning of ‘Catastrophic’ AI Risks
- Anthropic’s risk factors include the end of humanity, a feud with the Pentagon, and CEO Dario Amodei’s reputation
- Meta, SpaceX, Anthropic stoke the AI funding frenzy. What it means for our stocks
From AllMind Research
- AllMind Platform Feature Updates - Fall 2026
- AI Credit Covenant Monitoring: From Clause to Review
- AI-Led Expert Interviews vs. Transcript Libraries
- Run Cost-Controlled Financial Research in AllMind Agent Studio
- AllMind Discusses Ontario's AI Economy with Minister Stephen Crawford and Supply Ontario CEO James Wallace